Burrow TA - Search Results

1

Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapy.

Burrow TA, Cohen MB, Bokulic R, Deutsch G, Choudhary A, Falcone RA Jr, Grabowski GA. Burrow TA, et al. J Pediatr. 2007 Feb;150(2):202-6. doi: 10.1016/j.jpeds.2006.10.062. J Pediatr. 2007. PMID: 17236903

2

Non-lethal congenital hypotonia due to glycogen storage disease type IV.

Burrow TA, Hopkin RJ, Bove KE, Miles L, Wong BL, Choudhary A, Bali D, Li SC, Chen YT. Burrow TA, et al. Am J Med Genet A. 2006 Apr 15;140(8):878-82. doi: 10.1002/ajmg.a.31166. Am J Med Genet A. 2006. PMID: 16528737

3

Enzyme reconstitution/replacement therapy for lysosomal storage diseases.

Burrow TA, Hopkin RJ, Leslie ND, Tinkle BT, Grabowski GA. Burrow TA, et al. Curr Opin Pediatr. 2007 Dec;19(6):628-35. doi: 10.1097/MOP.0b013e3282f161f2. Curr Opin Pediatr. 2007. PMID: 18025928 Review.

4

Cardiac disease in methylmalonic acidemia.

Prada CE, Al Jasmi F, Kirk EP, Hopp M, Jones O, Leslie ND, Burrow TA. Prada CE, et al. Among authors: burrow ta. J Pediatr. 2011 Nov;159(5):862-4. doi: 10.1016/j.jpeds.2011.06.005. Epub 2011 Jul 23. J Pediatr. 2011. PMID: 21784454

5

Velaglucerase alfa in the treatment of Gaucher disease type 1.

Burrow TA, Grabowski GA. Burrow TA, et al. Clin Investig (Lond). 2011 Feb;1(2):285-293. doi: 10.4155/cli.10.21. Clin Investig (Lond). 2011. PMID: 21927713 Free PMC article.

6

Recurrent pancreatitis in ornithine transcarbamylase deficiency.

Prada CE, Kaul A, Hopkin RJ, Page KI, Nathan JD, Bartholomew DW, Cohen MB, Heubi JE, Leslie ND, Burrow TA. Prada CE, et al. Among authors: burrow ta. Mol Genet Metab. 2012 Aug;106(4):482-4. doi: 10.1016/j.ymgme.2012.06.005. Epub 2012 Jun 15. Mol Genet Metab. 2012. PMID: 22728053

7

CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings.

Burrow TA, Sun Y, Prada CE, Bailey L, Zhang W, Brewer A, Wu SW, Setchell KDR, Witte D, Cohen MB, Grabowski GA. Burrow TA, et al. Mol Genet Metab. 2015 Feb;114(2):233-241. doi: 10.1016/j.ymgme.2014.08.011. Epub 2014 Sep 2. Mol Genet Metab. 2015. PMID: 25219293 Free PMC article.

8

Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.

Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Ross L, Angell J, Puga AC. Cox TM, et al. Among authors: burrow ta. Lancet. 2015 Jun 13;385(9985):2355-62. doi: 10.1016/S0140-6736(14)61841-9. Epub 2015 Mar 26. Lancet. 2015. PMID: 25819691 Clinical Trial.

9

Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States.

Balwani M, Burrow TA, Charrow J, Goker-Alpan O, Kaplan P, Kishnani PS, Mistry P, Ruskin J, Weinreb N. Balwani M, et al. Among authors: burrow ta. Mol Genet Metab. 2016 Feb;117(2):95-103. doi: 10.1016/j.ymgme.2015.09.002. Epub 2015 Sep 7. Mol Genet Metab. 2016. PMID: 26387627 Free article. Review.

10

Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy.

Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Goker-Alpan O, Watman N, El-Beshlawy A, Kishnani PS, Pedroso ML, Gaemers SJM, Tayag R, Peterschmitt MJ. Cox TM, et al. Among authors: burrow ta. Blood. 2017 Apr 27;129(17):2375-2383. doi: 10.1182/blood-2016-12-758409. Epub 2017 Feb 6. Blood. 2017. PMID: 28167660 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

44 results

Search Page